

ConTTRIBUTE: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

NCT04561518

Status RECRUITING
Sponsor Alnylam Pharmaceuticals
Enrollment 1,500 participants

Key Eligibility Criteria

Inclusion (2)

- Diagnosis of ATTR amyloidosis or documented known disease-causing TTR variant for the cohort of pre-symptomatic carriers
- Germany Only: Patients must be treated per the summary of product characteristics (SmPC) for any approved treatment for ATTR amyloidosis

Exclusion (1)

- Current enrollment in a clinical trial for any investigational agent

Locations (40 total)

Clinical Trial Site, La Jolla, California, United States
Clinical Trial Site, Los Angeles, California, United States
Clinical Trial Site, Jacksonville, Florida, United States
... and 37 more locations